Toxicitystudy of SMMU-13, a biosimilar of bevacizumab,in cynomolgus monkeys

Jin-feng LI,Jia-yue YU,Xiao-yu DAI,Hai ZHU,Xiao-dong ZHANG,Xiu-guo HUA

DOI: https://doi.org/10.3969/J.ISSN.1671-9964.2018.01.013

2018-01-01

Abstract:The purpose of this study was to evaluate the toxicity of SMMU-13,a biosimilar of bevacizumab,in cynomolgus monkeys.Thirty healthy cynomolgus monkeys were randomly assigned to 5 groups (each group contained three male and three female monkeys) as follows.negative control,positive control,low-,mid-and high-dose groups.The low-,mid-,and high-dose groups were administered 2,10,and 50 mg/kg test article,respectively.The positive control group was given 50 mg/kg bevacizumab,and the negative control animals were given the SMMU-13 placebo.Animals were intravenously treated twice a week for 4 weeks following a 4-week recovery phase.The dose volume was 2.0 mL/kg in all groups.The abnormal findings were recorded.Compared with d0,lactate dehydrogenase (LDH) and triglyceride (TG) in animals from positive control,mid-and high-dose groups increased after administration of the Bevacizumab or SMMU-13.The femoral epiphyseal plate chondrocytes hyperplasia and calcified ossification were noted at male animals in high-dose group and positive control group.The damage was also observed in several animals at the intravenous injection sites or other tissues.No other abnormal findings were noted.The above results show that the main toxic target organs of SMMU-13 are physeal displasia and administration sites.The digestive system (liver) was also considered to be affected.In these experimental conditions,the no observed adverse effect level (NOAEL) of SMMU-13 is 2 mg/kg,and the toxic dose is 10 mg/kg.The SMMU-13 and bevacizumab showed similar pharmaceutical activity and toxicity profiles.